CALIFORNIA HEART CENTER FOUNDATION: Form 990, tax year 2012
View the entire original 990 at ProPublica ↗
- Organization
- CALIFORNIA HEART CENTER FOUNDATION (EIN 95-4772979)
- Tax period
- 2012-01-01 to 2012-12-31
- Filed
- 2013-11-11
- IRS object ID
- 201343169349301469
- Schema version
- 2012v2.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Timestamp | 2013-11-11T16:34:54-06:00 | Timestamp |
| Tax Period End Date | 2012-12-31 | TaxPeriodEndDate |
Preparer Firm PreparerFirm
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 346565596 | EIN |
Preparer Firm Business Name PreparerFirmBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ERNST & YOUNG US LLP | BusinessNameLine1 |
Preparer Firm US Address PreparerFirmUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 18111 VON KARMAN AVENUE SUITE 1000 | AddressLine1 |
| City | IRVINE | City |
| State | CA | State |
| ZIP Code | 92612 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnType |
| Tax Period Begin Date | 2012-01-01 | TaxPeriodBeginDate |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 954772979 | EIN |
Name Name
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CALIFORNIA HEART CENTER FOUNDATION | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Control | CALI | NameControl |
| Phone | 3102488327 | Phone |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 8536 WILSHIRE BOULEVARD 3RD FLOOR | AddressLine1 |
| City | BEVERLY HILLS | City |
| State | CA | State |
| ZIP Code | 90211 | ZIPCode |
Officer Officer
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name | THOMAS D GORDON | Name |
| Title | CFO | Title |
| Phone | 3102488327 | Phone |
| Date Signed | 2013-11-11 | DateSigned |
| Authorize Third Party | 1 | AuthorizeThirdParty |
Preparer Preparer
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name | KARA ADAMS | Name |
| PTIN | P00023315 | PTIN |
| Phone | 9497942300 | Phone |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax Year | 2012 | TaxYear |
| Build TS | 2016-03-07 17:11:31Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Of Principal Officer Person | ERIC N MARTON | NameOfPrincipalOfficerPerson |
Address Principal Officer US AddressPrincipalOfficerUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 8536 WILSHIRE BOULEVARD 3RD FLOOR | AddressLine1 |
| City | BEVERLY HILLS | City |
| State | CA | State |
| ZIP Code | 90211 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | 1535178 | GrossReceipts |
| Group Return For Affiliates | 0 | GroupReturnForAffiliates |
| Organization501c3 | X | Organization501c3 |
| Web Site | WWW.CALHEART.ORG | WebSite |
| Type Of Organization Corporation | X | TypeOfOrganizationCorporation |
| Year Formation | 2000 | YearFormation |
| State Legal Domicile | CA | StateLegalDomicile |
| Activity Or Mission Description | PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. | ActivityOrMissionDescription |
| Nbr Voting Members Governing Body | 17 | NbrVotingMembersGoverningBody |
| Nbr Independent Voting Members | 12 | NbrIndependentVotingMembers |
| Total Nbr Employees | 0 | TotalNbrEmployees |
| Total Nbr Volunteers | 13 | TotalNbrVolunteers |
| Total Gross UBI | 0 | TotalGrossUBI |
| Net Unrelated Business Txbl Income | 0 | NetUnrelatedBusinessTxblIncome |
| Contributions Grants Prior Year | 1280861 | ContributionsGrantsPriorYear |
| Contributions Grants Current Year | 1445229 | ContributionsGrantsCurrentYear |
| Program Service Revenue Prior Year | 29520 | ProgramServiceRevenuePriorYear |
| Program Service Revenue CY | 60983 | ProgramServiceRevenueCY |
| Investment Income Prior Year | 19031 | InvestmentIncomePriorYear |
| Investment Income Current Year | -232193 | InvestmentIncomeCurrentYear |
| Other Revenue Prior Year | 0 | OtherRevenuePriorYear |
| Other Revenue Current Year | 0 | OtherRevenueCurrentYear |
| Total Revenue Prior Year | 1329412 | TotalRevenuePriorYear |
| Total Revenue Current Year | 1274019 | TotalRevenueCurrentYear |
| Grants And Similar Amnts Prior Year | 0 | GrantsAndSimilarAmntsPriorYear |
| Grants And Similar Amnts CY | 7000 | GrantsAndSimilarAmntsCY |
| Benefits Paid To Members Prior Year | 0 | BenefitsPaidToMembersPriorYear |
| Benefits Paid To Members CY | 0 | BenefitsPaidToMembersCY |
| Salaries Etc Prior Year | 1113280 | SalariesEtcPriorYear |
| Salaries Etc Current Year | 1256527 | SalariesEtcCurrentYear |
| Total Prof Fundrsng Exp Prior Year | 0 | TotalProfFundrsngExpPriorYear |
| Total Prof Fundrsng Exp CY | 0 | TotalProfFundrsngExpCY |
| Total Fundrsng Exp Current Year | 0 | TotalFundrsngExpCurrentYear |
| Other Expense Prior Year | 458228 | OtherExpensePriorYear |
| Other Expenses Current Year | 444383 | OtherExpensesCurrentYear |
| Total Expenses Prior Year | 1571508 | TotalExpensesPriorYear |
| Total Expenses Current Year | 1707910 | TotalExpensesCurrentYear |
| Revenues Less Expenses Prior Year | -242096 | RevenuesLessExpensesPriorYear |
| Revenues Less Expenses CY | -433891 | RevenuesLessExpensesCY |
| Total Assets BOY | 966262 | TotalAssetsBOY |
| Total Assets EOY | 568742 | TotalAssetsEOY |
| Total Liabilities BOY | 81870 | TotalLiabilitiesBOY |
| Total Liabilities EOY | 99768 | TotalLiabilitiesEOY |
| Net Assets Or Fund Balances BOY | 884392 | NetAssetsOrFundBalancesBOY |
| Net Assets Or Fund Balances EOY | 468974 | NetAssetsOrFundBalancesEOY |
| Info In Schedule O Part III | X | InfoInScheduleOPartIII |
| Mission Description | THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. | MissionDescription |
| Significant New Program Services | 0 | SignificantNewProgramServices |
| Significant Change | 0 | SignificantChange |
| Expense | 1208332 | Expense |
| Grants | 7000 | Grants |
| Revenue | 60983 | Revenue |
| Description | THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2012: * SUCCESS WITH FAILURE: THE NURSING PERSPECTIVE OF HEART FAILURE, MECHANICAL CIRCULATORY SUPPORT AND TRANSPLANTATION: SPONSORED JOINTLY BY THE CEDARS-SINAI HEART INSTITUTE IN COLLABORATION WITH THE BRAWERMAN NURSING INSTITUTE AND THE CALIFORNIA CHAPTER OF THE AMERICAN COLLEGE OF CARDIOLOGY, "SUCCESS WITH FAILURE" WAS HELD ON JUNE 7TH, 2012 IN UNIVERSAL CITY, CALIFORNIA. THE MEETING WAS DESIGNED TO PROVIDE A FORUM FOR CRITICAL CARE NURSES, NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, CASE MANAGERS AND OTHER ALLIED HEALTH PROFESSIONALS TO DISCUSS ADVANCES IN THE TREATMENT AND MANAGEMENT OF PATIENTS WITH ADVANCED HEART DISEASE. THE CONFERENCE WAS ATTENDED BY 400 NURSE PROFESSIONALS FROM CENTERS ACROSS SOUTHERN CALIFORNIA. WITH JON KOBASHIGAWA SERVING AS A CONFERENCE ADVISOR AND CHAIR OF THE PLANNING COMMITTEE, THE CONFERENCE WAS EXTREMELY WELL RECEIVED. * INVESTIGATOR MEETING FOR RADB253 MULTI-CENTER/MULTI-NATIONAL LONG TERM FOLLOW-UP STUDY: WITH AN APPROVED INVESTIGATOR-INITIATED RESEARCH GRANT FROM NOVARTIS, DR. KOBASHIGAWA IS SERVING AS THE PRINCIPAL INVESTIGATOR (AND CEDARS-SINAI AS THE COORDINATING SITE) FOR THE RAD B253 LONG TERM FOLLOW-UP STUDY, A STUDY WHICH WILL EXAMINE THE TEN-YEAR OUTCOMES OF SUBJECTS ENROLLED IN THE LANDMARK RAD B253 STUDY EVALUATING THE EFFICACY AND SAFETY FOR EVEROLIUMUS (A NOVEL IMMUNOSUPPRESSION AGENT). IN ADVANCE OF STUDY INITIATION, DR. KOBASHIGAWA CHAIRED AN INVESTIGATORS MEETING IN TANDEM WITH THE INTERNATIONAL SOCIETY FOR HEART & LUNG TRANSPLANTATION IN PRAGUE, CZECH REPUBLIC, ON APRIL 17TH, 2012.* "OPTIMAL CARE AND NEW THERAPIES FOR ADVANCED HEART DISEASE": THIS ONE-DAY SYMPOSIUM ON HEART FAILURE AND HEART TRANSPLANTATION WAS HELD ON SATURDAY, MAY 12, 2012 IN VENTURA, CALIFORNIA AND ON SATURDAY, SEPTEMBER 15TH, 2012 IN RIVERSIDE, CALIFORNIA. THE PROGRAM FEATURED PRESENTATIONS ON TOPICS RELATED TO THE DIAGNOSIS AND TREATMENT OF HEART FAILURE AND TRANSPLANTATION FOR THE BENEFIT OF COMMUNITY PHYSICIANS, NURSES AND ALLIED HEALTH PROFESSIONALS. * SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS WERE OFFERED TO EIGHT STUDENTS IN MAY 2012. THESE INTERNSHIPS PROVIDED STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WILL BE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDED A FIRST YEAR MEDICAL STUDENT FROM NEW YORK UNIVERSITY, AND UNDERGRADUATE STUDENTS FROM COLUMBIA UNIVERSITY, EMORY UNIVERSITY, UC SANTA BARBARA, UCLA, USC AND LOYOLA MARYMOUNT UNIVERSITY.* PATIENT EDUCATION SERIES: PATIENT LECTURES BY DR. JON KOBASHIGAWA WERE ORGANIZED ON MAY 10TH, 2012 AND ON NOVEMBER 29TH, 2012 IN LOS ANGELES. COVERING "CURRENT TRENDS IN HEART TRANSPLANTATION", THE PROGRAM PROVIDED BOTH PRE AND POST TRANSPLANT PATIENTS WITH AN OVERVIEW OF ADVANCES IN THE FIELD OF HEART TRANSPLANTATION AND INCLUDED AN EXTENSIVE QUESTION AND ANSWER SESSION. RESEARCH STUDIES (ONGOING AND NEWLY INITIATED):STUDY TITLE: EARLY INVASIVE MONITORING ATTENUATION THROUGH GENE EXPRESSION (EIMAGE)PROJECT STATUS: PUBLICATION IN PROCESS.SPONSOR: EXPRESSION DIAGNOSTICS INC.PROJECT SUMMARY: THE PURPOSE OF THIS STUDY IS TO COMPARE THE SAFETY AND EFFECTIVENESS OF GENE EXPRESSION BLOOD TESTS TO THE COMMONLY USED METHOD OF HEART BIOPSIES FOR MONITORING ACUTE REJECTION IN PATIENTS WHO HAVE HAD A HEART TRANSPLANT. THE STUDY AIMS TO DEMONSTRATE THAT ACUTE REJECTION OF THE TRANSPLANTED HEART CAN BE SAFELY MONITORED USING THIS BLOOD TEST, FIRST COMMERCIALLY INTRODUCED IN 2005, SO THAT REPEATED HEART BIOPSIES CAN BE AVOIDED. THIS BLOOD TEST, CALLED GENE EXPRESSION PROFILING (GEP) IDENTIFIES THE EXPRESSION OF GENES ON WHITE BLOOD CELLS THAT CIRCULATE IN THE BLOOD AND CAUSE THE HEART TO BE REJECTED. RESULTS FROM THE TRIAL WERE PRESENTED AT THE 2013 INTERNATIONAL SOCIETY FOR HEART & LUNG TRANSPLANTATION ANNUAL MEETING AND SCIENTIFIC SESSIONS IN MONTREAL, CANADA. A MANUSCRIPT IS CURRENTLY IN PROGRESS, WITH EXPECTED PUBLICATION IN 2013.STUDY TITLE: CLINICAL TRIALS IN ORGAN TRANSPLANTATION (CTOT-11): NOVEL THERAPIES TO IMPROVE RENAL AND CARDIAC ALLOGRAFT OUTCOMESPROJECT STATUS: ENROLLINGSPONSOR: NIH/BRIGHAM AND WOMEN'S HOSPITALPROJECT SUMMARY: TRANSPLANTATION IS THE IDEAL THERAPY FOR END STAGE HEART AND END STAGE KIDNEY FAILURE, BUT ALLOGRAFT SURVIVAL AND FUNCTION REMAIN SUBOPTIMAL. THE OVERRIDING CLINICAL HYPOTHESIS IS THAT SPECIFICALLY DESIGNED THERAPIES GUIDED BY RATIONALLY CHOSEN NONINVASIVE IMMUNE MONITORING WILL IMPROVE OUTCOMES IN HEART AND KIDNEY TRANSPLANT RECIPIENTS. THE STUDY INVOLVES IDENTIFYING HEART TRANSPLANT CANDIDATES AT HIGH RISK FOR ANTIBODY MEDIATED INJURY (HIGH PRA) AND PERFORMING A PILOT STUDY TO DETERMINE THE SAFETY AND EFFICACY OF DESENSITIZATION USING A COMBINATION OF B CELL DEPLETION (RITUXIMAB) AND IVIG PLASMAPHERESIS. THE STUDY WILL TEST THE HYPOTHESIS THAT DESENSITIZATION WILL LOWER PRA, DIMINISH THE WAITING TIME TO HEART TRANSPLANTATION AND RESULT IN ACCEPTABLE 1 YEAR GRAFT SURVIVAL AND FUNCTION. ASSOCIATED MECHANISTIC STUDIES WILL DETERMINE HOW THE DESENSITIZATION PROTOCOL IMPACTS PREFORMED ALLOREACTIVE T AND B CELL IMMUNITY AND WILL TEST THE HYPOTHESIS THAT RESIDUAL B AND T CELL IMMUNE MEMORY WITH REACTIVITY TO DONOR ANTIGENS MEDIATES POST-TRANSPLANT ALLOGRAFT INJURY.STUDY TITLE: ADVANCED HEART DISEASE REGISTRY STUDYIRB STATUS: APPROVED/ENROLLINGSPONSOR: INTERNALPROJECT SUMMARY: HEART FAILURE IS A COMPLEX PROGRESSIVE MULTISYSTEM DISEASE STATE AFFECTING OVER 5 MILLION AMERICANS WITH SIGNIFICANT MORBIDITY AND MORTALITY. THERE HAS BEEN SIGNIFICANT IMPROVEMENT IN THE SURVIVAL OF PATIENTS DIAGNOSED WITH HEART FAILURE OVER RECENT YEARS WITH MUCH BEING OWED TO MEDICAL THERAPY ADVANCES AND A DEEPER KNOWLEDGE OF THE NEURO-HORMONAL CONTRIBUTION TO THIS CONDITION. WITH A YEARLY INCIDENCE OF 500,000 NEWLY DIAGNOSED HEART FAILURE PATIENTS, HEART FAILURE CONTINUES TO BE A MAJOR PUBLIC HEALTH BURDEN, AND IS THE MOST COMMON REASON FOR HOSPITAL ADMISSION FOR PATIENTS ABOVE 65 YEARS OF AGE. DESPITE SIGNIFICANT IMPROVEMENT IN MORBIDITY AND MORTALITY OVER TIME, HEART FAILURE REMAINS A CHRONIC DISEASE CHARACTERIZED BY RECURRENT DECOMPENSATIONS AND PERSISTENT SYMPTOMS. THE PURPOSE OF THIS CLINICAL RESEARCH IS TO RETROSPECTIVELY REVIEW DATA ON PATIENTS DIAGNOSED WITH HEART FAILURE, INCLUDING THOSE WHO ARE MAINTAINED ON MEDICAL THERAPY, THOSE WHO RECEIVE A HEART TRANSPLANT AND THOSE WHO RECEIVE MECHANICAL CIRCULATORY SUPPORT. THE RESEARCH WILL ADDRESS A VARIETY OF FACTORS INCLUDING QUALITY OF LIFE, CLINICAL OUTCOMES, MEDICAL AND SURGICAL THERAPIES, COMPLIANCE, USE OF INOTROPES, GENDER DIFFERENCES, AGE DIFFERENCES, SEXUAL DYSFUNCTION, VENTRICULAR ASSIST DEVICES, OBESITY, DIET, NUTRITION, PSYCHOSOCIAL FACTORS, PATHOLOGY DATA, LAB VALUES, SPIRITUALITY COUNSELING, PALLIATIVE CARE INTERVENTIONS, REHOSPITALIZATIONS, CLINICAL INTERVENTIONS, HEMODYNAMIC CHANGES, AND THE IMPACT ON BOTH SHORT-TERM AND LONG-TERM SURVIVAL AND QUALITY OF LIFE. BY EVALUATING THE DATA OF ALL OF OUR ADVANCED HEART DISEASE PATIENTS IN ONE COMPREHENSIVE DATABASE STUDY, WE HOPE TO IMPROVE OUR UNDERSTANDING OF HEART FAILURE AS WELL AS IMPROVE THE QUALITY OF LIFE OF OUR ADVANCED HEART DISEASE PATIENTS. TO DATE, 792 ADVANCED HEART DISEASE PATIENTS AT CEDARS-SINAI HAVE BEEN CONSENTED FOR THIS STUDY. PATIENT CONSENTING AND DATA COLLECTION CONTINUES. | Description |
| Total Program Service Expense | 1208332 | TotalProgramServiceExpense |
| Described In501 C3 | 1 | DescribedIn501C3 |
| Schedule B Required | 1 | ScheduleBRequired |
| Political Activities | 0 | PoliticalActivities |
| Lobbying Activities | 0 | LobbyingActivities |
| Subject To Proxy Tax | 0 | SubjectToProxyTax |
| Donor Advised Funds | 0 | DonorAdvisedFunds |
| Conservation Easements | 0 | ConservationEasements |
| Collections Of Art | 0 | CollectionsOfArt |
| Credit Counseling | 0 | CreditCounseling |
| Term Or Permanent Endowments | 0 | TermOrPermanentEndowments |
| Report Land Bldg Equip | 1 | ReportLandBldgEquip |
| Report Invest Oth Securities | 0 | ReportInvestOthSecurities |
| Report Prog Rel Invest | 0 | ReportProgRelInvest |
| Report Other Assets | 0 | ReportOtherAssets |
| Report Other Liabilities | 0 | ReportOtherLiabilities |
| Report Fin48 Footnote | 0 | ReportFin48Footnote |
| Independent Audit Financial Stmt | 0 | IndependentAuditFinancialStmt |
| Consolidated Audit Financial Stmt | 0 | ConsolidatedAuditFinancialStmt |
| School | 0 | School |
| Foreign Office | 0 | ForeignOffice |
| Foreign Activities | 0 | ForeignActivities |
| More Than5000 K To Organizations | 0 | MoreThan5000KToOrganizations |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividuals |
| Professional Fundraising | 0 | ProfessionalFundraising |
| Fundraising Activities | 0 | FundraisingActivities |
| Gaming | 0 | Gaming |
| Hospital | 0 | Hospital |
| Grants To Organizations | 1 | GrantsToOrganizations |
| Grants To Individuals | 0 | GrantsToIndividuals |
| Schedule J Required | 1 | ScheduleJRequired |
| Tax Exempt Bonds | 0 | TaxExemptBonds |
| Excess Benefit Transaction | 0 | ExcessBenefitTransaction |
| Prior Excess Benefit Transaction | 0 | PriorExcessBenefitTransaction |
| Loan To Officer Or DQP | 0 | LoanToOfficerOrDQP |
| Grant To Related Person | 0 | GrantToRelatedPerson |
| Bsnss Rltnshp With Organization | 0 | BsnssRltnshpWithOrganization |
| Bsnss Rltnshp Thru Family Member | 0 | BsnssRltnshpThruFamilyMember |
| Officer Entity With Bsnss Rltnshp | 0 | OfficerEntityWithBsnssRltnshp |
| Deductible Non Cash Contributions | 0 | DeductibleNonCashContributions |
| Deductible Contributions Of Art | 0 | DeductibleContributionsOfArt |
| Terminated | 0 | Terminated |
| Partial Liquidation | 0 | PartialLiquidation |
| Disregarded Entity | 0 | DisregardedEntity |
| Related Entity | 1 | RelatedEntity |
| Related Org Controlled Entity | 1 | RelatedOrgControlledEntity |
| Transaction Related Entity | 0 | TransactionRelatedEntity |
| Transfers To Exempt Non Chrtbl Org | 0 | TransfersToExemptNonChrtblOrg |
| Activities Conducted Partnership | 0 | ActivitiesConductedPartnership |
| Schedule O Required | 1 | ScheduleORequired |
| Number Forms Transmitted With1096 | 1 | NumberFormsTransmittedWith1096 |
| Number W2 G Included | 0 | NumberW2GIncluded |
| Compliance With Backup Witholding | 1 | ComplianceWithBackupWitholding |
| Number Of Employees | 0 | NumberOfEmployees |
| Unrelated Business Income | 0 | UnrelatedBusinessIncome |
| Foreign Financial Account | 0 | ForeignFinancialAccount |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTrans |
| Taxable Party Notification | 0 | TaxablePartyNotification |
| Non Deductible Contributions | 0 | NonDeductibleContributions |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributions |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOf |
| Funds To Pay Premiums | 0 | FundsToPayPremiums |
| Premiums Paid | 0 | PremiumsPaid |
| Indoor Tanning Services | 0 | IndoorTanningServices |
| Info In Schedule O Part VI | X | InfoInScheduleOPartVI |
| Nbr Voting Governing Body Members | 17 | NbrVotingGoverningBodyMembers |
| Number Independent Voting Members | 12 | NumberIndependentVotingMembers |
| Family Or Business Relationship | 1 | FamilyOrBusinessRelationship |
| Delegation Of Management Duties | 0 | DelegationOfManagementDuties |
| Changes To Organizing Docs | 0 | ChangesToOrganizingDocs |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuse |
| Members Or Stockholders | 1 | MembersOrStockholders |
| Election Of Board Members | 1 | ElectionOfBoardMembers |
| Decisions Subject To Approval | 1 | DecisionsSubjectToApproval |
| Minutes Of Governing Body | 1 | MinutesOfGoverningBody |
| Minutes Of Committees | 1 | MinutesOfCommittees |
| Officer Mailing Address | 0 | OfficerMailingAddress |
| Local Chapters | 0 | LocalChapters |
| Form990 Provided To Governing Body | 0 | Form990ProvidedToGoverningBody |
| Conflict Of Interest Policy | 1 | ConflictOfInterestPolicy |
| Annual Disclosure Covered Persons | 1 | AnnualDisclosureCoveredPersons |
| Regular Monitoring Enforcement | 1 | RegularMonitoringEnforcement |
| Whistleblower Policy | 0 | WhistleblowerPolicy |
| Document Retention Policy | 0 | DocumentRetentionPolicy |
| Compensation Process CEO | 0 | CompensationProcessCEO |
| Compensation Process Other | 1 | CompensationProcessOther |
| Investment In Joint Venture | 0 | InvestmentInJointVenture |
| States Where Copy Of Return Is Filed | CA | StatesWhereCopyOfReturnIsFiled |
| Upon Request | X | UponRequest |
The Books Are In Care Of TheBooksAreInCareOf
Name Business NameBusiness
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ERIC MARTON | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Telephone Number | 3102488327 | TelephoneNumber |
Address US AddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 8536 WILSHIRE BOULEVARD 3RD FLOOR | AddressLine1 |
| City | BEVERLY HILLS | City |
| State | CA | State |
| ZIP Code | 90211 | ZIPCode |
Form990 Part VII Section A Form990PartVIISectionA (21 entries)
| TitleTitle | Average Hours Per WeekAverageHoursPerWeek | Individual Trustee Or DirectorIndividualTrusteeOrDirector | OfficerOfficer | Reportable Comp From OrganizationReportableCompFromOrganization | Reportable Comp From Related OrgsReportableCompFromRelatedOrgs | Other CompensationOtherCompensation | Average Hours Per Week RelatedAverageHoursPerWeekRelated | Highest Compensated EmployeeHighestCompensatedEmployee |
|---|---|---|---|---|---|---|---|---|
| JON KOBASHIGAWA MD | ||||||||
| CHIEF MEDICAL DIRECTOR | 2.00 | X | X | 500 | 0 | 0 | ||
| KEENAN BEHRLE | ||||||||
| CHAIRPERSON | 2.00 | X | X | 0 | 0 | 0 | ||
| JAMES HAMILTON | ||||||||
| SECRETARY | 2.00 | X | X | 0 | 0 | 0 | ||
| KAY DILLARD | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| THOMAS D GORDON | ||||||||
| CFO | 1.00 | X | X | 0 | 987640 | 169379 | 65.00 | |
| RUSSELL FAUCETT | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| IRENE FURLONG | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| MICHELE HAMILTON MD | ||||||||
| DIRECTOR | 2.00 | X | 500 | 0 | 0 | |||
| RICHARD B JACOBS | ||||||||
| DIRECTOR | 1.00 | X | 0 | 950959 | 224975 | 61.00 | ||
| E ERIC JOHNSON | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| JOSEPH O LAMPE | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| EDUARDO MARBAN MD | ||||||||
| DIRECTOR | 1.00 | X | 0 | 2363995 | 219036 | 60.00 | ||
| LAURENCE MARTON MD | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| ARTHUR J OCHOA | ||||||||
| DIRECTOR | 1.00 | X | 0 | 675668 | 64223 | 65.00 | ||
| WILLIAM OUCHI PHD | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| EDWARD PRUNCHUNAS | ||||||||
| DIRECTOR | 1.00 | X | 0 | 1813534 | 114144 | 65.00 | ||
| LAWRENCE SOUZA PHD | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| PHILLIP L WILLIAMS | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| ERIC N MARTON | ||||||||
| PRESIDENT | 30.00 | X | 0 | 321749 | 40893 | 30.00 | ||
| CHRISTINE SUMBI | ||||||||
| VICE-PRESIDENT | 40.00 | X | 0 | 126340 | 16560 | |||
| DONNA MASER | ||||||||
| REGISTERED NURSE | 40.00 | 0 | 117182 | 34200 | X | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | 1000 | TotalReportableCompFromOrg |
| Total Reportable Comp Frm Rltd Orgs | 7357067 | TotalReportableCompFrmRltdOrgs |
| Total Other Compensation | 883410 | TotalOtherCompensation |
| Number Individuals GT100 K | 0 | NumberIndividualsGT100K |
| Formers Listed | 0 | FormersListed |
| Total Comp GT150 K | 1 | TotalCompGT150K |
| Compensation From Other Sources | 0 | CompensationFromOtherSources |
| Number Of Contractors GT100 K | 0 | NumberOfContractorsGT100K |
| Related Organizations | 1435022 | RelatedOrganizations |
| All Other Contributions | 10207 | AllOtherContributions |
| Total Contributions | 1445229 | TotalContributions |
Program Service Revenue ProgramServiceRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| Description | EDUCATIONAL PROGRAMS | Description |
| Business Code | 611430 | BusinessCode |
| Total Revenue Column | 60983 | TotalRevenueColumn |
| Related Or Exempt Function Income | 60983 | RelatedOrExemptFunctionIncome |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | 60983 | TotalProgramServiceRevenue |
Investment Income InvestmentIncome
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 12225 | TotalRevenueColumn |
| Exclusion | $12,225 | ExclusionAmount |
Gross Amount Sales Assets GrossAmountSalesAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | 16741 | Securities |
Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | 0 | Securities |
| Other | 261159 | Other |
Gain Or Loss GainOrLoss
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | 16741 | Securities |
| Other | -261159 | Other |
Net Gain Or Loss Investments NetGainOrLossInvestments
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -244418 | TotalRevenueColumn |
| Related Or Exempt Function Income | -261159 | RelatedOrExemptFunctionIncome |
| Exclusion | $16,741 | ExclusionAmount |
Total Revenue TotalRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 1274019 | TotalRevenueColumn |
| Related Or Exempt Function Income | -200176 | RelatedOrExemptFunctionIncome |
| Unrelated Business Revenue | 0 | UnrelatedBusinessRevenue |
| Exclusion | $28,966 | ExclusionAmount |
Grants To Domestic Orgs GrantsToDomesticOrgs
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 7000 | Total |
| Program Services | 7000 | ProgramServices |
Comp Current Officers Directors CompCurrentOfficersDirectors
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 325843 | Total |
| Management And General | 325843 | ManagementAndGeneral |
Other Salaries And Wages OtherSalariesAndWages
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 708795 | Total |
| Program Services | 708795 | ProgramServices |
Pension Plan Contributions PensionPlanContributions
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 37394 | Total |
| Program Services | 37394 | ProgramServices |
Other Employee Benefits OtherEmployeeBenefits
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 128530 | Total |
| Program Services | 128530 | ProgramServices |
Payroll Taxes PayrollTaxes
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 55965 | Total |
| Program Services | 55965 | ProgramServices |
Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 2500 | Total |
| Management And General | 2500 | ManagementAndGeneral |
Fees For Services Other FeesForServicesOther
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 32022 | Total |
| Program Services | 22736 | ProgramServices |
| Management And General | 9286 | ManagementAndGeneral |
Advertising Advertising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 1200 | Total |
| Management And General | 1200 | ManagementAndGeneral |
Office Expenses OfficeExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 12966 | Total |
| Program Services | 8362 | ProgramServices |
| Management And General | 4604 | ManagementAndGeneral |
Information Technology InformationTechnology
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 7584 | Total |
| Program Services | 3792 | ProgramServices |
| Management And General | 3792 | ManagementAndGeneral |
Occupancy Occupancy
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 188113 | Total |
| Program Services | 188113 | ProgramServices |
Travel Travel
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 6241 | Total |
| Program Services | 6241 | ProgramServices |
Conferences Meetings ConferencesMeetings
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 147077 | Total |
| Management And General | 147077 | ManagementAndGeneral |
Depreciation Depletion DepreciationDepletion
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 29940 | Total |
| Program Services | 29940 | ProgramServices |
Other Expenses OtherExpenses (4 entries)
| DescriptionDescription | TotalTotal | Program ServicesProgramServices | Management And GeneralManagementAndGeneral |
|---|---|---|---|
| DUES & SUBSCRIPTIONS | 5156 | 5156 | |
| BANK/CREDIT CARD FEES | 2425 | 2425 | |
| STORAGE | 1740 | 1740 | |
| LICENSES & TAXES | 1679 | 1679 |
All Other Expenses AllOtherExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 5740 | Total |
| Program Services | 4568 | ProgramServices |
| Management And General | 1172 | ManagementAndGeneral |
Total Functional Expenses TotalFunctionalExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 1707910 | Total |
| Program Services | 1208332 | ProgramServices |
| Management And General | 499578 | ManagementAndGeneral |
| Fundraising | 0 | Fundraising |
Cash Non Interest Bearing CashNonInterestBearing
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 66614 | BOY |
| EOY | 110187 | EOY |
Savings And Temp Cash Investments SavingsAndTempCashInvestments
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 14678 | BOY |
| EOY | 15650 | EOY |
Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 4687 | BOY |
| EOY | 20435 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Buildings Equipment Basis | 93433 | LandBuildingsEquipmentBasis |
| Land Bldg Equipment Accum Deprec | 74554 | LandBldgEquipmentAccumDeprec |
Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 309978 | BOY |
| EOY | 18879 | EOY |
Investments Pub Traded Securities InvestmentsPubTradedSecurities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 559744 | BOY |
| EOY | 403591 | EOY |
Other Assets Total OtherAssetsTotal
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 10561 | BOY |
| EOY | 0 | EOY |
Total Assets TotalAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 966262 | BOY |
| EOY | 568742 | EOY |
Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 81870 | BOY |
| EOY | 99768 | EOY |
Total Liabilities TotalLiabilities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 81870 | BOY |
| EOY | 99768 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Follow SFAS117 | X | FollowSFAS117 |
Unrestricted Net Assets UnrestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 884392 | BOY |
| EOY | 468974 | EOY |
Total Net Assets Fund Balances TotalNetAssetsFundBalances
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 884392 | BOY |
| EOY | 468974 | EOY |
Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 966262 | BOY |
| EOY | 568742 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expenses | -433891 | ReconcilationRevenueExpenses |
| Reconciliation Unrealized Invest | 18473 | ReconciliationUnrealizedInvest |
| Reconcilation Other Changes | 0 | ReconcilationOtherChanges |
| Method Of Accounting Accrual | X | MethodOfAccountingAccrual |
| Accountant Compile Or Review | 0 | AccountantCompileOrReview |
| FS Audited | 0 | FSAudited |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequired |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Publicly Supported Org170b1 Avi | X | PubliclySupportedOrg170b1Avi |
Gifts Grants Contrib Received170 GiftsGrantsContribReceived170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 1380752 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 1202798 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 2355777 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 1280861 | CurrentTaxYearMinus1Year |
| Current Tax Year | 1445229 | CurrentTaxYear |
| Total | 7665417 | Total |
Total170 Total170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 1380752 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 1202798 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 2355777 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 1280861 | CurrentTaxYearMinus1Year |
| Current Tax Year | 1445229 | CurrentTaxYear |
| Total | 7665417 | Total |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Amounts Subst Contributors Total | 2735128 | AmountsSubstContributorsTotal |
| Public Support Total170 | 4930289 | PublicSupportTotal170 |
Gross Investment Income170 GrossInvestmentIncome170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 11200 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 7427 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 12029 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 18834 | CurrentTaxYearMinus1Year |
| Current Tax Year | 12225 | CurrentTaxYear |
| Total | 61715 | Total |
Net UBI NetUBI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 25 | CurrentTaxYearMinus4Years |
| Total | 25 | Total |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | 7727157 | TotalSupport |
| Gross Receipts From Admissions Etc | 276421 | GrossReceiptsFromAdmissionsEtc |
| Public Support Pertcentage170 | 0.63800 | PublicSupportPertcentage170 |
| Public Support Pertcent Prior Year | 0.54130 | PublicSupportPertcentPriorYear |
| Thirty Three Percnt Tests CY170 | X | ThirtyThreePercntTestsCY170 |
Schedule B IRS990ScheduleB
Contributor Info ContributorInfo
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor Number | RESTRICTED | ContributorNumber |
Contributor Name Business ContributorNameBusiness
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor Address US ContributorAddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Aggregate Contributions | RESTRICTED | AggregateContributions |
Schedule D IRS990ScheduleD
Equipment Equipment
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | 56349 | OtherCostOrOtherBasis |
| Depreciation | 50714 | Depreciation |
| Book Value | 5635 | BookValue |
Other Land Buildings OtherLandBuildings
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | 37084 | OtherCostOrOtherBasis |
| Depreciation | 23840 | Depreciation |
| Book Value | 13244 | BookValue |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Of Book Value Land Buildings | 18879 | TotalOfBookValueLandBuildings |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Records Maintained | 0 | RecordsMaintained |
Recipient Table RecipientTable
Recipient Name Business RecipientNameBusiness
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE HEART FOUNDATION | BusinessNameLine1 |
Address US AddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 31822 VILLAGE CENTER RD STE 208 | AddressLine1 |
| City | WESTLAKE VILLAGE | City |
| State | CA | State |
| ZIP Code | 91361 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN Of Recipient | 450471117 | EINOfRecipient |
| IRC Section | 501(C)(3) | IRCSection |
| Amount Of Cash Grant | 6500 | AmountOfCashGrant |
| Purpose Of Grant | GENERAL SUPPORT | PurposeOfGrant |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Nbr Of501 C3 And Govt Grants | 1 | TotalNbrOf501C3AndGovtGrants |
| Total Nbr Of Other Organizations | 0 | TotalNbrOfOtherOrganizations |
Form990 Schedule I Part IV Form990ScheduleIPartIV
| Field | Value | IRS element (for citing) |
|---|---|---|
| Explanation | SCHEDULE I, PART I, LINE 2: THE ORGANIZATION CONTRIBUTES TO WELL-ESTABLISHED EXEMPT ORGANIZATIONS AND RELIES ON THE GOVERNING BODY OF EACH OF THESE ORGANIZATIONS TO ENSURE THAT GRANT FUNDS DONATED TO EACH AND EVERY ORGANIZATION ARE USED FOR PROPER PURPOSES AND NOT OTHERWISE DIVERTED FROM THE INTENDED USE. | Explanation |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Severance Payment | 0 | SeverancePayment |
| Supplemental Nonqual Retire Plan | 1 | SupplementalNonqualRetirePlan |
| Equity Based Comp Arrangement | 0 | EquityBasedCompArrangement |
| Comp Based On Revenue Of Filing Org | 0 | CompBasedOnRevenueOfFilingOrg |
| Comp Based On Revenue Related Orgs | 0 | CompBasedOnRevenueRelatedOrgs |
| Comp Based Net Earnings Filing Org | 0 | CompBasedNetEarningsFilingOrg |
| Comp Based Net Earnings Relate Orgs | 0 | CompBasedNetEarningsRelateOrgs |
| Any Non Fixed Payments | 0 | AnyNonFixedPayments |
| Initial Contract Exception | 0 | InitialContractException |
Form990 Schedule J Part II Form990ScheduleJPartII (7 entries)
| TitleTitle | Base Compensation Filing OrgBaseCompensationFilingOrg | Comp Based On Related OrgsCompBasedOnRelatedOrgs | Bonus Filing OrgBonusFilingOrg | Bonus Related OrgsBonusRelatedOrgs | Other Compensation Filing OrgOtherCompensationFilingOrg | Other Compensation Related OrgsOtherCompensationRelatedOrgs | Deferred Comp Filing OrgDeferredCompFilingOrg | Deferred Comp Related OrgsDeferredCompRelatedOrgs | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg | Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs | Total Compensation Filing OrgTotalCompensationFilingOrg | Total Compensation Related OrgsTotalCompensationRelatedOrgs | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg | Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THOMAS D GORDON | ||||||||||||||
| CFO | 0 | 483754 | 0 | 253126 | 0 | 250760 | 0 | 137382 | 0 | 31997 | 0 | 1157019 | 0 | 0 |
| RICHARD B JACOBS | ||||||||||||||
| DIRECTOR | 0 | 526308 | 0 | 208827 | 0 | 215824 | 0 | 207416 | 0 | 17559 | 0 | 1175934 | 0 | 0 |
| EDUARDO MARBAN MD | ||||||||||||||
| DIRECTOR | 0 | 1219053 | 0 | 728927 | 0 | 416015 | 0 | 179624 | 0 | 39412 | 0 | 2583031 | 0 | 0 |
| ARTHUR J OCHOA | ||||||||||||||
| DIRECTOR | 0 | 404099 | 0 | 172344 | 0 | 99225 | 0 | 25771 | 0 | 38452 | 0 | 739891 | 0 | 0 |
| EDWARD PRUNCHUNAS | ||||||||||||||
| DIRECTOR | 0 | 638179 | 0 | 248133 | 0 | 927222 | 0 | 83825 | 0 | 30319 | 0 | 1927678 | 0 | 298488 |
| ERIC N MARTON | ||||||||||||||
| PRESIDENT | 0 | 293399 | 0 | 2750 | 0 | 25600 | 0 | 12304 | 0 | 28589 | 0 | 362642 | 0 | 0 |
| DONNA MASER | ||||||||||||||
| REGISTERED NURSE | 0 | 117182 | 0 | 0 | 0 | 0 | 0 | 11860 | 0 | 22340 | 0 | 151382 | 0 | 0 |
Form990 Schedule J Part III Form990ScheduleJPartIII (2 entries)
| Return ReferenceReturnReference | ExplanationExplanation | IdentifierIdentifier |
|---|---|---|
| PART I, LINE 4B | THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. IN 2012 ONE INDIVIDUAL RECEIVED A PAYOUT FROM AMOUNTS ACCRUED IN A PRIOR YEAR. IN ADDITION, ONE INDIVIDUAL HAS A RETENTION INCENTIVE WHICH HAD A CLIFF VESTING DATE IN 2012. THE FOLLOWING OFFICERS, DIRECTORS, KEY EMPLOYEES AND HIGHEST-COMPENSATED EMPLOYEES RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2012. THOMAS D. GORDON 224,515 RICHARD B. JACOBS 177,862 EDUARDO MARBAN, MD 329,985 ERIC N. MARTON 23,485 ARTHUR J. OCHOA 96,750 EDWARD PRUNCHUNAS 867,658 | |
| PART III | SCHEDULE J, PART I, LINE 3: THE PRESIDENT IS COMPENSATED BY A RELATED ORGANIZATION. PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, LINE 15. | SUPPLEMENTAL INFORMATION |
Schedule O IRS990ScheduleO
General Explanation GeneralExplanation (11 entries)
| IdentifierIdentifier | Return ReferenceReturnReference | ExplanationExplanation |
|---|---|---|
| PROGRAM SERVICE STATEMENT | STUDY TITLE: HEARTSBREATH TEST FOR HEART TRANSPLANT REJECTION | PROJECT STATUS: ENROLLMENT COMPLETE SPONSOR: MENSANNA RESEARCH PROJECT SUMMARY: THIS RESEARCH WILL EVALUATE WHETHER THE HEARTSBREATH DEVICE CAN ASSIST IN DIAGNOSING HEART TRANSPLANT REJECTION IN PATIENTS WHO HAVE RECEIVED A HEART TRANSPLANT DURING THE PRECEDING 12 MONTHS AND ARE ABOUT TO RECEIVE AN ENDOMYOCARDIAL BIOPSY. THE MAIN AIM OF THIS STUDY IS TO VALIDATE THE ACCURACY OF THE DEVICE TO DETECT HEART TRANSPLANT REJECTION, BY COLLECTING SAMPLES PRIOR TO BIOPSY AND COMPARING THEM WITH THE BIOPSY RESULTS. PATIENTS WHO HAVE RECEIVED A HEART TRANSPLANT WITHIN THE PREVIOUS 12 MONTHS AND ARE SCHEDULED FOR A ROUTINE ENDOMYOCARDIAL BIOPSY MAY BE ELIGIBLE FOR PARTICIPATION IN THIS TRIAL. THE BREATH TEST USES BIOMARKERS FOUND IN HUMAN BREATH AS INDICATORS FOR REJECTION AND ITS INTENSITY. A SCREENING BREATH TEST COULD POTENTIALLY IDENTIFY TRANSPLANT RECIPIENTS AT LOW RISK OF GRADE 3 REJECTION AND REDUCE THE NUMBER OF ENDOMYOCARDIAL BIOPSIES. THIS MULTI-CENTER TRIAL COMPLETED ENROLLMENT IN AUGUST 2013. STUDY TITLE: ACE INHIBITION AND CARDIAC ALLOGRAFT VASCULOPATHY PROJECT STATUS: ENROLLING SPONSOR: NIH/STANFORD UNIVERSITY PROJECT SUMMARY: THE PURPOSE OF THIS STUDY IS TO INVESTIGATE THE EFFECT OF THE ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE I), RAMIPRIL, AN ANTIHYPERTENSIVE AGENT, ON THE DEVELOPMENT OF CARDIAC ALLOGRAFT VASCULOPATHY (CAV) IN CARDIAC TRANSPLANT RECIPIENTS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. CAV IS A LEADING CAUSE OF MORBIDITY AND MORTALITY AFTER HEART TRANSPLANT. DESPITE ADVANCES IN PROPHYLAXIS AGAINST REJECTION AND INFECTION, AS WELL AS IMPROVED CONTROL OF TRADITIONAL ATHEROSCLEROTIC RISK FACTORS, SIGNIFICANT DEVELOPMENT OF ATHEROSCLEROTIC PLAQUE AND DETRIMENTAL VASCULAR REMODELING OCCUR EARLY AFTER ORTHOTOPIC HEART TRANSPLANTATION (OHT). THE INVESTIGATORS HOPE TO DETERMINE WHETHER ACE I THERAPY WITH RAMIPRIL EARLY AFTER OHT IMPACTS THE DEVELOPMENT OF CAV, AND LEARN IF THE USE OF ACE I INCREASES THE NUMBER OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS RESULTING IN IMPROVED ENDOTHELIAL FUNCTION AND LESS ATHEROSCLEROSIS. THE PRIMARY OBJECTIVE IS TO INVESTIGATE THE EFFECT OF ACE I ON THE DEVELOPMENT OF CAV IN CARDIAC TRANSPLANT RECIPIENTS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. STUDY TITLE: LONG TERM OUTCOME FOLLOW-UP OF THE RAD001 B253 STUDY, EVEROLIMUS FOR THE PREVENTION OF ALLOGRAFT REJECTION AND VASCULOPATHY IN CARDIAC-TRANSPLANT RECIPIENTS SPONSOR: NOVARTIS PROJECT SUMMARY: SURVIVAL FOR TRANSPLANT RECIPIENTS IS STILL LIMITED BY CAV, INFECTIOUS COMPLICATIONS, MALIGNANCY, AND REJECTION. IN THE LANDMARK HEART TRANSPLANT STUDY RAD001 B253 WITH ALL GROUPS GIVEN CYCLOSPORINE, BOTH DOSES OF EVEROLIMUS (1.5 AND 3 MG/DAY) WERE SUPERIOR TO AZATHIOPRINE FOR EFFICACY FAILURE AT 6, 12, AND 24 MONTHS POST TRANSPLANTATION. THIS FINDING WAS PRIMARILY DUE TO A REDUCTION IN THE INCIDENCE OF ACUTE REJECTION (ISHLT = GRADE 3A) IN THE EVEROLIMUS GROUPS. THE RAD B253 STUDY ALSO CONFIRMED THAT EVEROLIMUS APPEARED TO BE MORE BENEFICIAL THAN AZATHIOPRINE IN REDUCING THE SEVERITY AND INCIDENCE OF CAV AT 1-YEAR POST TRANSPLANTATION. HOWEVER, THE LONG TERM BENEFIT OF EVEROLIMUS IN HEART TRANSPLANT PATIENTS HAS YET TO BE ESTABLISHED AND THUS, A STUDY EVALUATING LONG-TERM OUTCOMES IS WARRANTED. THE PURPOSE OF THE THIS STUDY IS TO COMPARE THE 10-YEAR OUTCOMES OF CARDIAC TRANSPLANT PATIENTS ORIGINALLY RANDOMIZED TO EVEROLIMUS 1.5MG, EVEROLIMUS 3.0MG AND AZATHIOPRINE GROUPS FROM THE MULTI-CENTER RAD001 B253 STUDY. THESE OUTCOMES INCLUDE SURVIVAL, CAV BY ANGIOGRAPHY, AND NON-FATAL MAJOR ADVERSE CARDIAC EVENTS. THIS IS AN INVESTIGATOR-INITIATED STUDY WHERE CEDARS-SINAI IS SERVING AS THE COORDINATING SITE, GATHERING LONG-TERM FOLLOW UP DATA ON PATIENTS FROM THE ORIGINAL STUDY. IN COLLABORATION WITH THE CEDARS-SINAI ENTERPRISE INFORMATION SERVICES GROUP, A WEB-BASED ELECTRONIC DATA CAPTURE (EDC) SYSTEM HAS BEEN DEVELOPED AND WAS LAUNCHED IN JANUARY 2013. TO DATE, SUBCONTRACTS WITH 16 EXTERNAL SITES HAVE BEEN COMPLETED, WITH EXTERNAL SITES NOW ACTIVELY ENTERING THEIR DATA INTO THE EDC SYSTEM. DATA COLLECTION IS EXPECTED TO BE COMPLETE THIS FALL. THE SCOPE OF WORK FOR THIS PROJECT WAS ALSO RECENTLY AMENDED TO INCLUDE A NEW INTRAVASCULAR ULTRASOUND (IVUS) SUB-ANALYSIS, TO BE PERFORMED IN COLLABORATION WITH THE CLEVELAND CLINIC, WHICH SERVED AS THE IVUS CORE LAB FOR THE ORIGINAL STUDY. STUDY TITLE: CLINICAL TRIALS IN ORGAN TRANSPLANTATION (CTOT-13): A PROSPECTIVE, RANDOMIZED, MULTICENTER, TWO-PARALLEL ARM STUDY EVALUATING THE OVERALL EFFICACY AND SAFETY OF DESENSITIZATION THERAPY ON SELECT SENSITIZED PATIENTS AWAITING HEART TRANSPLANTATION PROJECT STATUS: ENROLLING SPONSOR: NIH/MOUNT SINAI PROJECT SUMMARY: BECAUSE IT HAS BEEN DIFFICULT TO FIND APPROPRIATE ORGANS FOR HIGHLY SENSITIZED HEART TRANSPLANT CANDIDATES, SEVERAL GROUPS HAVE DEVELOPED DESENSITIZATION APPROACHES AIMED AT REMOVING OR BLOCKING THE EFFECTOR FUNCTIONS OF PREFORMED ANTIBODIES. THIS STUDY IS A CONTROLLED PILOT TRIAL WITH ASSOCIATED MECHANISTIC STUDIES TO ASSESS THE SAFETY, EFFICACY AND ASSOCIATED MECHANISMS OF DESENSITIZATION THERAPY IN HEART TRANSPLANTATION USING A STRATEGY THAT INCLUDES PLASMAPHERESIS AND BORTEZOMIB PRE-TRANSPLANTATION. THE EVALUATION OF EFFICACY IS DEFINED BY A LOWER COMPLICATION RATE WHILE ON THE HEART TRANSPLANT WAITLIST. THE SECONDARY OBJECTIVE IS TO DETERMINE IF DESENSITIZATION THERAPY FOR THE SENSITIZED PATIENT DECREASES PRE-TRANSPLANT MORBIDITY AND MORTALITY WHILE ON THE WAITING LIST AND IMPROVES POST-TRANSPLANT OUTCOMES. STUDY TITLE: EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS: A SINGLE CENTER SURVEY STUDY SPONSOR: INTERNAL GRANT AWARD: N/A PROJECT SUMMARY: CARDIAC TRANSPLANTATION IS CURRENTLY THE PROCEDURE OF CHOICE FOR SELECTED PATIENTS WITH END-STAGE HEART DISEASE THAT IS NOT AMENABLE TO FURTHER MEDICAL INTERVENTION OR CONVENTIONAL CARDIAC PROCEDURES. WITH THE ADVENT OF MORE EFFECTIVE IMMUNOSUPPRESSIVE AGENTS, THE DEFINITION OF THE SUCCESSFULLY MANAGED HEART TRANSPLANT RECIPIENT IS EVOLVING BEYOND THE IMMEDIATE CHALLENGE OF PREVENTING ACUTE REJECTION. THE PURPOSE OF THIS SURVEY STUDY IS TO ASSESS A VARIETY OF FACTORS AND THEIR IMPACT ON BOTH SHORT-TERM AND LONG-TERM OUTCOMES AND QUALITY OF LIFE POST HEART TRANSPLANTATION. DATA TO BE COLLECTED WILL INCLUDE DEMOGRAPHIC DATA, PSYCHOSOCIAL DATA AND PHYSICAL DATA. AS OF OCTOBER 2013, 552 HEART TRANSPLANT RECIPIENTS HAVE COMPLETED THE SURVEY. DATA FROM THE SURVEY HAS BEEN UTILIZED FOR SEVERAL PUBLISHED RESEARCH ABSTRACTS, INCLUDING AN ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE 2013 INTERNATIONAL SOCIETY FOR HEART & LUNG TRANSPLANTATION ANNUAL MEETING AND SCIENTIFIC SESSIONS. STUDY TITLE: SYNCARDIA FREEDOM DRIVER SYSTEM STUDY SPONSOR: SYNCARDIA SYSTEMS, INC. PROJECT STATUS: ENROLLING PROJECT SUMMARY: ON 15 OCTOBER 2004, THE SYNCARDIA TEMPORARY TOTAL ARTIFICIAL HEART (TAH-T) RECEIVED FDA APPROVAL (PREMARKET APPROVAL APPLICATION #P030011) FOR IN-HOSPITAL USE AS A BRIDGE TO TRANSPLANT IN CARDIAC TRANSPLANT-ELIGIBLE CANDIDATES AT RISK OF IMMINENT DEATH FROM BIVENTRICULAR FAILURE. THE IMPLANTABLE TAH-T IS POWERED BY AN EXTERNAL PNEUMATIC DRIVER, THE CIRCULATORY SUPPORT SYSTEM (CSS) CONSOLE. BECAUSE THE SIZE AND WEIGHT OF THE CSS CONSOLE LIMIT THE MOBILITY OF TAH-T PATIENTS, SYNCARDIA DEVELOPED A SMALLER, PORTABLE EXTERNAL PNEUMATIC DRIVER, THE FREEDOM DRIVER SYSTEM, WHICH INCORPORATES SOME OF THE CSS CONSOLE OPERATING PARAMETERS TO PROVIDE THE PNEUMATIC SUPPORT REQUIRED BY THE IMPLANTED TAH-T IN CLINICALLY STABLE PATIENTS, WHILE ENHANCING THEIR MOBILITY. DESIGN VERIFICATION TEST RESULTS DEMONSTRATE THAT THE FREEDOM DRIVER OPERATES WITHIN THE SPECIFICATIONS OF THE CSS CONSOLE TO PROVIDE THE PULSATILE PNEUMATIC PRESSURES REQUIRED TO SUPPORT CLINICALLY STABLE TAH-T PATIENTS SAFELY IN AND OUT OF THE HOSPITAL. THIS CLINICAL STUDY IS INTENDED TO: * CONFIRM THE DESIGN VERIFICATION TEST RESULTS THAT DEMONSTRATED THAT THE FREEDOM DRIVER IS A SUITABLE PNEUMATIC DRIVER FOR CLINICALLY STABLE TAH-T PATIENTS AND * CONFIRM THAT PATIENTS AND LAY CAREGIVERS CAN BE TRAINED TO MANAGE THE FREEDOM DRIVER SYSTEM SAFELY OUTSIDE THE HOSPITAL. |
| FORM 990, PART IV, LINE 12 | THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/12 AND 6/30/13 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/12. | |
| STUDY TITLE: THE SYNCARDIA CARDIOWEST TEMPORARY TOTAL ARTIFICIAL HEART | (TAH-T) POSTMARKET SURVEILLANCE STUDY SPONSOR: SYNCARDIA SYSTEMS, INC. PROJECT STATUS: ENROLLING PROJECT SUMMARY: THE SYNCARDIA SYSTEMS, INC. TAH-T IS INDICATED FOR USE AS A BRIDGE TO TRANSPLANT IN CARDIAC TRANSPLANT-ELIGIBLE PATIENTS AT RISK OF IMMINENT DEATH FROM BIVENTRICULAR FAILURE. THE PIVOTAL CLINICAL INVESTIGATION SHOWED THAT THE DEVICE IS EFFECTIVE AS A BRIDGE TO TRANSPLANT IN PATIENTS WHO ARE AT IMMINENT RISK OF DYING FROM BIVENTRICULAR HEART FAILURE. THE DATA OBTAINED IN THIS TRIAL DEMONSTRATED THAT THE TAH-T IS EFFECTIVE CIRCULATORY SUPPORT FOR PATIENTS WAITING FOR DONOR HEARTS. MOREOVER, THE BENEFITS TO PATIENTS INCLUDE THE ADDITIONAL TIME TO AWAIT TRANSPLANT AND IMPROVED HEMODYNAMICS RESULTING IN EARLY AMBULATION. IN SUBJECTS IMPLANTED WITH THE TAH-T IN THE CLINICAL STUDY, THERE WAS AN IMMEDIATE AND SUSTAINED IMPROVEMENT IN HEMODYNAMIC STATUS (CARDIAC INDEX) AND IMPROVED RENAL AND HEPATIC FUNCTION. ONCE TRANSPLANTED, THE SUBJECT'S SURVIVAL WAS UNAFFECTED BY THE TIME SPENT ON THE TAH-T. THE TAH-T WAS SHOWN TO BE A SAFE AND EFFECTIVE BRIDGE-TO-TRANSPLANT DEVICE FOR PATIENTS WITH NON-REVERSIBLE BIVENTRICULAR HEART FAILURE, AT IMMINENT RISK OF DEATH, FOR WHOM NO OTHER OPTIONS ARE CURRENTLY AVAILABLE. THE PURPOSE OF THIS STUDY IS TO DEMONSTRATE THAT THE RESULTS ACHIEVED IN THE ORIGINAL PIVOTAL CLINICAL INVESTIGATION OF 81 SUBJECTS FROM FIVE CLINICAL SITES ARE GENERALIZABLE TO CLINICAL SITES THAT COMPLETE THE STAFF TRAINING DEFINED IN THE SYNCARDIA SYSTEMS, INC. TRAINING MANUAL AND WHO ENROLL SUBJECTS WHO MEET THE INTENDED USE DEFINED IN THE PRODUCT INSTRUCTIONS FOR USE. STUDY TITLE: PROSPECTIVE, MULTI-CENTER, RANDOMIZED CLINICAL INVESTIGATION OF TRANSMEDICS ORGAN CARE SYSTEM (OCS) FOR CARDIAC USE SPONSOR: TRANSMEDICS PROJECT SUMMARY: THE TRANSMEDICS OCS IS A PORTABLE ORGAN PERFUSION AND MONITORING SYSTEM INTENDED TO PRESERVE A DONATED HEART IN A BEATING STATE DURING TRANSPORT FOR THE EVENTUAL TRANSPLANTATION INTO A RECIPIENT. THE OCS MAINTAINS ORGAN VIABILITY BY PROVIDING A CONTROLLED ENVIRONMENT, CONTINUOUSLY PERFUSING THE DONATED HEART WITH WARM, OXYGENATED BLOOD, SUPPLEMENTED WITH THE TRANSMEDICS CARDIAC SOLUTION SET. THE BLOOD IS COLLECTED FROM THE DONOR AND IS CONTINUOUSLY CIRCULATED TO THE ORGAN IN A CLOSED CIRCUIT ALONG WITH THE CARDIAC SOLUTION SET. THE OCS PRESERVES THE HEART AND MONITORS THE ORGAN'S PERFUSION PARAMETERS IMMEDIATELY AFTER EXPLANTATION FROM A DONOR AND CONNECTION TO THE DEVICE, DURING TRANSPORTATION TO THE RECIPIENT SITE, AND UNTIL DISCONNECTION FROM THE DEVICE. THE PURPOSE OF THIS STUDY IS TO COMPARE THE SAFETY AND EFFECTIVENESS OF THE OCS WITH THE EXISTING COLD STATIC CARDIOPLEGIA STANDARD OF CARE FOR THE PRESERVATION OF DONOR HEARTS. AS OF OCTOBER 2013, CSMC HAS ENROLLED 39 SUBJECTS IN THIS STUDY AND IS THE HIGHEST ENROLLING SITE FOR THIS MULTI-CENTER TRIAL. TOTAL STUDY ENROLLMENT WAS EXPECTED TO BE COMPLETED IN AUGUST 2013. DATA ANALYSIS IS ONGOING. STUDY TITLE: THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY IN PRESENSITIZED PATIENTS RECEIVING CARDIAC TRANSPLANTATION: AN OPEN-LABEL, INVESTIGATOR-INITIATED PILOT TRIAL: [THE DUET CARDIAC TRIAL] SPONSOR: ALEXION PHARMACEUTICALS PROJECT STATUS: ENROLLING PROJECT SUMMARY: THE GROWING PROPORTION OF SENSITIZED CARDIAC RECIPIENTS PRESENTS AN ADDITIONAL CHALLENGE TO THE TRANSPLANT PRACTITIONER ATTEMPTING TO MINIMIZE THE OCCURRENCE OF ANTIBODY MEDIATED REJECTION (AMR). PATIENTS PRE-EXPOSED OR "SENSITIZED" TO ANTIGEN EXPOSING EVENTS (I.E.: BLOOD TRANSFUSIONS, MULTIPLE PREGNANCIES, PRIOR ORGAN TRANSPLANTATIONS, VENTRICULAR SUPPORT DEVICES) ARE MORE LIKELY TO BOTH POSSESS PREFORMED AND DEVELOP DE-NOVO ANTIBODIES. SENSITIZED PATIENTS WITH PANEL REACTIVE ANTIBODIES > 25% ARE AT RISK FOR INCREASED MORTALITY AFTER HEART TRANSPLANTATION. A CENTRAL COMPONENT OF ANTIBODY-MEDIATED CELL INJURY IS COMPLEMENT ACTIVATION. THE INHIBITION OF TERMINAL COMPLEMENT ACTIVATION MAY BE THE MISSING LINK TO DECREASING POSSIBLY BOTH COMPLEMENT-MEDIATED AMR AND CELLULAR REJECTION BY INHIBITING BOTH THE INFLAMMATORY EFFECTS OF BOTH CIRCULATING ANTIBODIES AND CYTOKINE INDUCED CELL DEATH. ECULIZUMAB IS A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO COMPLEMENT PROTEIN C5 WITH HIGH AFFINITY, THEREBY INHIBITING ITS CLEAVAGE TO C5A AND C5B AND PREVENTING THE GENERATION OF THE TERMINAL COMPLEMENT COMPLEX C5B-9. BY THIS MECHANISM, ECULIZUMAB INHIBITS TERMINAL COMPLEMENT MEDIATED INTRAVASCULAR HEMOLYSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS. THIS STUDY IS A NON-RANDOMIZED, OPEN-LABEL, INVESTIGATOR-INITIATED SAFETY AND EFFICACY TRIAL INVESTIGATING THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY TO PREVENT ANTIBODY MEDIATED REJECTION. THE DURATION OF THE STUDY WILL INCLUDE AN OPEN ENROLLMENT PERIOD AND AT LEAST 12 MONTHS OF FOLLOW-UP (POST-TRANSPLANT). THE TRIAL WILL ENROLL A TOTAL OF UP TO 10 "SENSITIZED" PATIENTS WITH A PANEL REACTIVE ANTIBODY SCORE OF GREATER THAN 70% AND NOT PREVIOUSLY OR CURRENTLY ENROLLED IN ANOTHER ONGOING TRIAL. AT THE TIME OF INITIAL BASELINE SCREENING PRIOR TO TRANSPLANTATION, PATIENTS WILLING TO CONSENT TO THE INVESTIGATIONAL USE OF ECULIZUMAB WILL BE ENROLLED IN THE TREATMENT ARM (COMPRISING A MAXIMUM OF 10 PATIENTS). THE USE OF ECULIZUMAB WILL BE UN-BLINDED TO ALL STUDY AND RESEARCH PRACTITIONER PARTICIPANTS. A HISTORICAL COHORT OF 10 ADDITIONAL PATIENTS WILL ALSO BE UTILIZED FOR COMPARISON. STUDY TITLE: A POSTMARKETING OBSERVATIONAL STUDY TO ASSESS RESPIRATORY TRACT ADVERSE EVENTS IN PULMONARY ARTERIAL HYPERTENSION PATIENTS WITH TYVASO(R) TREPROSTINIL INHALATION SOLUTION SPONSOR: UNITED THERAPEUTICS PROJECT SUMMARY: TREPROSTINIL IS AN INHALED PROSTACYCLIN VASODILATOR RECENTLY APPROVED IN THE US FOR GROUP 1 PULMONARY ARTERIAL HYPERTENSION PATIENTS. DURING THE APPROVAL PROCESS, THE FDA EXPRESSED CONCERNS THAT TREPROSTINIL MAY BE IRRITATING TO THE RESPIRATORY TRACT WHEN ADMINISTERED BY THE INHALATION ROUTE. THUS, A POST MARKETING REQUIREMENT HAS BEEN MANDATED, SPECIFICALLY A LONG-TERM OBSERVATIONAL STUDY TO FURTHER EVALUATE THE POTENTIAL ASSOCIATION BETWEEN TREPROSTINIL AND ORO-/NASOPHARYNGEAL AND PULMONARY ADVERSE EVENTS. THIS STUDY WILL BE A LONG-TERM OBSERVATIONAL STUDY IN THE US THAT WILL INCLUDE 1000 PATIENT-YEARS OF MONITORING IN TREPROSTINIL-TREATED PATIENTS, AND 1000 PATIENT-YEARS OF FOLLOW-UP IN MATCHED CONTROLS RECEIVING OTHER FDA APPROVED TREATMENTS FOR PULMONARY HYPERTENSION. THE PRIMARY OBJECTIVE OF THE STUDY IS TO DESCRIBE THE TYPE AND INCIDENCE OF ORO-/NASOPHARYNGEAL AND PULMONARY ADVERSE EVENTS THAT MAY BE ASSOCIATED WITH CURRENT OR RECENT TREATMENT WITH TREPROSTINIL FOR PAH. THE SECONDARY OBJECTIVE OF THE STUDY IS TO COMPARE THE INCIDENCE OF SELECTED ORO-/NASOPHARYNGEAL AND PULMONARY ADVERSE EVENTS IN PATIENTS TREATED WITH TREPROSTINIL FOR PAH WITH PATIENTS NOT TREATED WITH TREPROSTINIL FOR PAH. | |
| FORM 990, PART VI, SECTION A, LINE 2 | LAURENCE MARTON, MD, DIRECTOR AND ERIC MARTON, PRESIDENT HAVE A FAMILY RELATIONSHIP. | |
| FORM 990, PART VI, SECTION A, LINE 6 | CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. | |
| FORM 990, PART VI, SECTION A, LINE 7A | CEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. | |
| FORM 990, PART VI, SECTION A, LINE 7B | RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) SUBJECT TO SECTION 5.08, APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION | |
| FORM 990, PART VI, SECTION B, LINE 11 | THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. | |
| FORM 990, PART VI, SECTION B, LINE 12C | CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. | |
| FORM 990, PART VI, SECTION B, LINE 15B | THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES. | |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. |
Schedule R IRS990ScheduleR
Form990 Schedule R Part II Form990ScheduleRPartII (3 entries)
| Address Line1AddressUS/AddressLine1 | CityAddressUS/City | StateAddressUS/State | ZIP CodeAddressUS/ZIPCode | EINEIN | Primary ActivitiesPrimaryActivities | Legal Domicile StateLegalDomicileState | Exempt Code SectionExemptCodeSection | Public Charity StatusPublicCharityStatus | Direct Controlling Entity NADirectControllingEntityNA | Controlled OrgControlledOrg | Business Name Line1DirectControllingEntityName/BusinessNameLine1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CEDARS-SINAI MEDICAL CENTER | |||||||||||
| 8700 BEVERLY BOULEVARD | LOS ANGELES | CA | 90048 | 951644600 | HEALTHCARE | CA | 501(C)(3) | LINE 3 | N/A | 0 | |
| CEDARS-SINAI MEDICAL CARE FOUNDATION | |||||||||||
| 200 N ROBERTSON BOULEVARD 101 | BEVERLY HILLS | CA | 90211 | 954457756 | PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH | CA | 501(C)(3) | LINE 11A, I | 1 | CEDARS-SINAI MEDICAL CENTER | |
| (no name) | |||||||||||
| 1 | |||||||||||
Form990 Schedule R Part IV Form990ScheduleRPartIV (2 entries)
| Address Line1AddressUS/AddressLine1 | CityAddressUS/City | StateAddressUS/State | ZIP CodeAddressUS/ZIPCode | EINEIN | Primary ActivityPrimaryActivity | Legal Domicile StateLegalDomicileState | Direct Controlling Entity NADirectControllingEntityNA | Type Of EntityTypeOfEntity | Controlled OrgControlledOrg |
|---|---|---|---|---|---|---|---|---|---|
| GREATER VALLEY MANAGEMENT SERVICES ORGANIZATION INC | |||||||||
| 6500 WILSHIRE BLVD 8TH FLOOR | LOS ANGELES | CA | 90048 | 954439758 | MANAGEMENT FUNCTIONS | CA | N/A | C | 1 |
| OPTIMATRIX HEALTH SOLUTIONS INC | |||||||||
| 6500 WILSHIRE BLVD 9TH FLOOR | LOS ANGELES | CA | 90048 | 954522779 | INFORMATION SYSTEMS | CA | N/A | C | 1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Ann Rents Royalties | 0 | ReceiptOfIntAnnRentsRoyalties |
| Gift Grant Or Cap Contr To Other Org | 0 | GiftGrantOrCapContrToOtherOrg |
| Gift Grant Or Cap Contr Fr Other Org | 1 | GiftGrantOrCapContrFrOtherOrg |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrg |
| Loans Or Guarantees From Other Org | 0 | LoansOrGuaranteesFromOtherOrg |
| Dividends Related Organization | 0 | DividendsRelatedOrganization |
| Sale Of Assets To Other Org | 0 | SaleOfAssetsToOtherOrg |
| Purchase Of Assets From Other Org | 0 | PurchaseOfAssetsFromOtherOrg |
| Exchange Of Assets | 0 | ExchangeOfAssets |
| Rental Of Facilities To Other Orgs | 0 | RentalOfFacilitiesToOtherOrgs |
| Rental Of Facilities Fr Other Orgs | 0 | RentalOfFacilitiesFrOtherOrgs |
| Perform Of Services For Other Orgs | 0 | PerformOfServicesForOtherOrgs |
| Perform Of Services By Other Orgs | 0 | PerformOfServicesByOtherOrgs |
| Sharing Of Facilities | 0 | SharingOfFacilities |
| Sharing Of Paid Employees | 1 | SharingOfPaidEmployees |
| Reimbursement Paid To Other Org | 1 | ReimbursementPaidToOtherOrg |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrg |
| Other Transfer To Other Org | 0 | OtherTransferToOtherOrg |
| Other Transfer From Other Org | 0 | OtherTransferFromOtherOrg |
Comments